Childhood obesity and vitamin D deficiency by unknown
Central Journal of Endocrinology, Diabetes & Obesity
Cite this article: Wojcik M (2013) Childhood Obesity and Vitamin D Deficiency. J Endocrinol Diabetes Obes 1(1): 1004.
Corresponding author
Malgorzata Wojcik, Department of Pediatric and 
Adolescent Endocrinology, Chair of Pediatrics, Polish-
American Institute of Pediatrics, Jagiellonian University 
Medical College, Wielicka Street 265, 30-663 Krakow, 
Poland,  Tel : 48 12 658 12 77; Fax; 48 12 658 10 05; Email: 
malgorzata.wojcik@uj.edu.pl
Submitted: 18 July 2013
Accepted: 05 August 2013
Published: 07 August 2013
Copyright
© 2013 Wojcik
  OPEN ACCESS  
Review Article
Childhood Obesity and Vitamin 
D Deficiency
Malgorzata Wojcik* 
Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Polish-
American Institute of Pediatrics, Jagiellonian University Medical College, Poland
Abstract
The global escalation of childhood obesity and vitamin D deficiency are major 
public health issues. Both have been attributed to lifestyle changes. Obesity and 
vitamin D status are known to be associated, but the degree of linkage and whether it 
has any significance is unknown. Another important issue is the potential role of vitamin 
D in the development of the complications of obesity, because the health consequences 
of vitamin D deficiency in obese children and adolescents are not clear. This paper 
discussed the relationship between obesity and low vitamin D concentrations and its 
consequences, with reference to the possible underlying mechanisms. 
The global escalation of childhood obesity is a major public 
health issue. Despite a known genetic contribution, the increase 
in pediatric obesity has been attributed mainly to diet and a 
sedentary lifestyle. Another increasingly prevalent public health 
concern, probably caused mainly by the same lifestyle factors, 
is vitamin D deficiency. Both conditions are often associated, 
and many studies confirmed a high prevalence of the vitamin 
D deficiency in obese patients. In children and adolescents 
that are overweight and obese it affects approximately 60% in 
comparison to 20% of non obese subjects [1-4]. Moreover, 
an inverse correlation between body mass index, fat tissue 
content and vitamin D levels had been proven in many studies 
[1-5]. Obesity and vitamin D status are known to be associated, 
but the degree of linkage and whether it has any significance is 
unknown. A recently published metaanalysis of 21 adult cohorts 
(up to 42,024 participants) revealed  that higher BMI lead to 
lower vitamin D level, while any effects of lower increasing BMI 
are likely to be small [5].  These results confirm, that vitamin D 
deficiency is a consequence, not a cause of obesity, and that it is 
rather impossible, that vitamin D supplementation may assist 
in preventing or treating obesity. The possible explanations of 
a high prevalence of vitamin D deficiency in obese children and 
adolescents might be lower, compared to non obese children, 
dietary intake, reduced cutaneous synthesis due to less exposure 
to the sun, altered metabolism and sequestration in the adipose 
tissue. Despite these hypotheses, it had been shown in an elegant 
study of 686 community-dwelling individuals that a volumetric 
dilutional model accounted essentially for all the variability in 
serum vitamin D concentrations attributable to obesity. Even 
though the factors described above may be operative, they 
are effectively ―captured by body weight. Once serum 25D 
concentrations in obese individuals are adjusted for body size, 
there is no longer a difference between obese and non-obese 
individuals [6,7]. Although the association between obesity and 
in consequence low vitamin D concentrations is therefore well-
established, it remains uncertain what the health consequences 
of this might be. It has been suggested, that low vitamin D levels 
may contribute to the development of insulin resistance and 
subsequent metabolic alterations. A strong association between 
insulin resistance and an excess of fat tissue has been recognized 
for decades, but there is still confusion on what the risk factors 
are. One of the candidates is a low vitamin D level. Some authors 
have pointed to low vitamin D status as an important risk factor of 
insulin resistance and impaired glucose metabolism independent 
of body adiposity [1]. One of the possible explanations might 
be a potential anti-inflamatory role of vitamin D. Since the 
immunomodulatory functions of vitamin D are incontestable, 
its deficiency in obese patients may coincide with enhanced 
systemic inflammation. It has also been shown that low-grade 
inflammation is associated with reduced insulin sensitivity. This 
theory has been supported by the results of a recently published 
pediatric study. The results showed an association between 
low vitamin D level, and activation of a pro-inflammatory, pro-
diabetic and atherogenic pathways in obese children. It might 
justify an attempt to inhibit this process and prevent or treat 
metabolic syndrome by vitamin D supplementation [4]. Despite 
these promising results, another study failed to demonstrate any 
reduction in systemic inflammatory markers in adult participants 
receiving 7000 IU oral vitamin D daily [8]. There is a clear need 
for adequately-powered, prospective interventions in pediatric 
populations. To date the role of vitamin D supplementation in 
obesity prevention has been uncertain. Novel insights into the 
potential contribution of vitamin D in the development of insulin 
resistance were possible after the discovery of FGF, especially 
FGF23 and its endocrine action [9]. It has been shown that FGF23 
may play a key role in the early phase of the decrease in insulin 
sensitivity in obese adolescents [10,11]. It has the potential to 
act as a hormone, and is pivotal in the control of phosphate and 
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vitamin D metabolism. However the exact mechanisms of the 
contribution of FGF23 to alterations in insulin metabolism in 
obese patients remains unclear, recent studies conducted on mice 
indicate that insulin signaling, or fat metabolism disturbances in 
the genetically ablated FGF23 subjects are mediated by vitamin 
D [12,13]. Some studies have pointed to the presence of low 
FGF23 levels in vitamin D deficient individuals, however it was 
not confirmed in larger groups [13]. Moreover, recent studies 
explicitly negate a simple correlation between vitamin D levels 
and insulin resistance in obese adolescents. They have shown 
that low vitamin D levels are one of the possible consequences 
of obesity rather than an independent risk factor of insulin 
resistance [2,3]. 
CONCLUSIONS
Obesity, and perhaps vitamin D deficiency, are among the 
most important modifiable risk factors for in number of chronic 
diseases. Nevertheless it remains controversial whether their 
association is significant, or if is a coincidental occurrence of 
two conditions with similar origin. However interventions to 
reduce BMI are expected to decrease the prevalence of vitamin D 
deficiency, the results of the vitamin D supplementation  in obese 
patients remain unknown.  
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